<p>Praxis Investment Management Inc. 在最近向證券交易委員會的披露中表示，在第二季度將其在強生（NYSE:JNJ - 免費報告）的持倉減少了 24.0%。該機構投資者在此期間出售了 15,670 股後，持有 49,661 股該公司的股票。強生約佔 Praxis Investment Management Inc.投資組合的 0.5%，是其第 29 大持倉。Praxis Investment Management Inc.在強生的持股在最近的報告期末價值為 7,586,000 美元。</p>
<p>獲取 <strong>強生</strong> 的提醒：</p>
<ul>
<li>強生的併購策略才是投資者真正關注的故事</li>
</ul>
<p>其他一些機構投資者和對沖基金最近也增加或減少了對該公司的持股。Commons Capital LLC 在第二季度將其在強生的持倉增加了 19.0%。Commons Capital LLC 目前持有 1,826 股該公司的股票，價值 279,000 美元，此前在上個季度又購買了 291 股。Harbor Asset Planning Inc.在第二季度獲得了強生的新持倉，價值約為 142,000 美元。Werba Rubin Papier Wealth Management 在第二季度將其在強生的持倉增加了 19.5%。Werba Rubin Papier Wealth Management 目前持有 2,892 股該公司的股票，價值 442,000 美元，此前在上個季度又購買了 471 股。Turtle Creek Wealth Advisors LLC 在第二季度獲得了強生的新持倉，價值約為 1,224,000 美元。最後，WealthPlan Investment Management LLC 在第二季度將其在強生的持倉增加了 20.2%。WealthPlan Investment Management LLC 目前持有 70,070 股該公司的股票，價值 10,703,000 美元，此前在上個季度又購買了 11,759 股。目前 69.55% 的股票由機構投資者和對沖基金持有。</p>
<h2>分析師升級和降級</h2>
<p>強生的股票曾多次成為研究分析師報告的主題。Cowen 在週二的研究報告中重申了對強生股票的 “買入” 評級。富國銀行在 10 月 3 日的研究報告中對強生股票設定了 212.00 美元的目標價，並給予該股票 “超配” 評級。摩根士丹利在週三的研究報告中對強生股票設定了 190.00 美元的目標價。巴克萊在 7 月 17 日的研究報告中將強生股票的目標價從 165.00 美元提高至 176.00 美元，並給予該股票 “持平” 評級。最後，Stifel Nicolaus 在週三的研究報告中將強生股票的目標價從 165.00 美元提高至 190.00 美元，並給予該股票 “持有” 評級。兩位股票研究分析師對該股票給予了強烈買入評級，十二位給予了買入評級，八位給予了持有評級。根據 MarketBeat.com 的數據，該股票的平均評級為 “適度買入”，共識目標價為 199.59 美元。</p>
<ul>
<li>強生股票可以繼續上漲，因為戰略奏效</li>
</ul>
<p><strong>查看我們關於 JNJ 的最新報告</strong></p>
<h2>內部人士買賣</h2>
<p>在其他消息中，執行副總裁 Jennifer L. Taubert 在 9 月 4 日（星期四）出售了 56,471 股該公司的股票。股票以 177.81 美元的平均價格出售，總價值為 10,041,108.51 美元。交易完成後，該執行副總裁持有 178,013 股公司股票，價值 31,652,491.53 美元。這代表其持股減少了 24.08%。該交易已在向證券交易委員會的備案中披露，相關信息可通過 SEC 網站獲取。內部人士持有該公司 0.16% 的股票。</p>
<h2>強生股票上漲 0.6%</h2>
<ul>
<li>為什麼 AbbVie 和強生可能會超越輝瑞</li>
</ul>
<p>強生在週五的開盤價為 193.27 美元。該公司的債務與股本比率為 0.50，流動比率為 1.01，速動比率為 0.76。該公司的市值為 4654.5 億美元，市盈率為 18.65，市盈增長比率為 2.27，貝塔係數為 0.40。該公司有 50 日簡單移動平均線為 180.49 美元，200 日簡單移動平均線為 164.86 美元。強生的 52 周低點為 140.68 美元，52 周高點為 194.40 美元。</p>
<p>強生（NYSE:JNJ - 獲取免費報告）最近在 8 月 30 日（星期三）發佈了季度財報。該公司報告本季度每股收益為 2.26 美元。該業務在本季度的收入為 240.2 億美元。強生的淨利潤率為 27.26%，股本回報率為 33.08%。平均而言，賣方分析師預計強生在當前年度的每股收益為 10.58 美元。</p>
<h2>強生宣佈分紅</h2>
<p>該公司最近還宣佈了季度分紅，將於 12 月 9 日（星期二）支付。11 月 25 日（星期二）的股東將獲得 1.30 美元的分紅。這代表每年 5.20 美元的分紅和 2.7% 的收益率。該分紅的除息日為 11 月 25 日（星期二）。強生的分紅支付比率目前為 50.19%。</p>
<h2>強生公司簡介</h2>
<p>（免費報告）</p>
<p>強生是一家控股公司，專注於醫療保健領域的產品研究、開發、生產和銷售。它通過創新藥物和醫療技術兩個部門運營。創新藥物部門專注於免疫學、傳染病、神經科學、腫瘤學、心血管和代謝以及肺動脈高壓。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，勝過強生</li>
<li>目前有哪些值得購買的大盤股？</li>
<li>強生的併購策略才是投資者真正需要關注的故事</li>
<li>如何開始投資於便士股票</li>
<li>特斯拉：一些分析師預測將下跌 30%——該恐慌了嗎？</li>
<li>科技股解析：你需要了解的科技知識</li>
<li>對美元的對沖基金態度轉變——這三隻股票的買入信號？</li>
</ul>
<p><strong>想看看其他對強生持有股份的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取強生（NYSE:JNJ - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元於強生嗎？</h2>
<p>在考慮強生之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而強生並不在名單上。</p>
<p>雖然強生目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

強生

<p>Praxis Investment Management Inc. 在第二季度將其在強生（NYSE: JNJ）的持股減少了 24%，目前持有 49,661 股，價值約 759 萬美元。該頭寸佔其投資組合的約 0.5%。其他機構投資者也調整了他們的持股，其中 Commons Capital LLC 和 WealthPlan Investment Management LLC 的增持尤為顯著。分析師對 JNJ 保持總體積極的展望，普遍目標價為 199.59 美元，評級從強烈買入到持有不等</p>

<p>Praxis Investment Management Inc. cut its position in Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 24.0% during the second quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The institutional investor owned 49,661 shares of the company's stock after selling 15,670 shares during the period. Johnson &amp; Johnson accounts for about 0.5% of Praxis Investment Management Inc.'s investment portfolio, making the stock its 29th biggest position. Praxis Investment Management Inc.'s holdings in Johnson &amp; Johnson were worth $7,586,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Praxis Investment Management Inc. 在最近向證券交易委員會的披露中表示，在第二季度將其在強生（NYSE:JNJ - 免費報告）的持倉減少了 24.0%。該機構投資者在此期間出售了 15,670 股後，持有 49,661 股該公司的股票。強生約佔 Praxis Investment Management Inc.投資組合的 0.5%，是其第 29 大持倉。Praxis Investment Management Inc.在強生的持股在最近的報告期末價值為 7,586,000 美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>強生</strong> 的提醒：</p>
</div><ul>
<li>Johnson &amp; Johnson's M&amp;A Strategy Is the Real Story for Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>強生的併購策略才是投資者真正關注的故事</li>
</ul>
</div><p>A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Commons Capital LLC boosted its position in Johnson &amp; Johnson by 19.0% in the second quarter. Commons Capital LLC now owns 1,826 shares of the company's stock valued at $279,000 after buying an additional 291 shares in the last quarter. Harbor Asset Planning Inc. acquired a new position in Johnson &amp; Johnson in the second quarter valued at about $142,000. Werba Rubin Papier Wealth Management boosted its position in Johnson &amp; Johnson by 19.5% in the second quarter. Werba Rubin Papier Wealth Management now owns 2,892 shares of the company's stock valued at $442,000 after buying an additional 471 shares in the last quarter. Turtle Creek Wealth Advisors LLC acquired a new position in Johnson &amp; Johnson in the second quarter valued at about $1,224,000. Finally, WealthPlan Investment Management LLC boosted its position in Johnson &amp; Johnson by 20.2% in the second quarter. WealthPlan Investment Management LLC now owns 70,070 shares of the company's stock valued at $10,703,000 after buying an additional 11,759 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些機構投資者和對沖基金最近也增加或減少了對該公司的持股。Commons Capital LLC 在第二季度將其在強生的持倉增加了 19.0%。Commons Capital LLC 目前持有 1,826 股該公司的股票，價值 279,000 美元，此前在上個季度又購買了 291 股。Harbor Asset Planning Inc.在第二季度獲得了強生的新持倉，價值約為 142,000 美元。Werba Rubin Papier Wealth Management 在第二季度將其在強生的持倉增加了 19.5%。Werba Rubin Papier Wealth Management 目前持有 2,892 股該公司的股票，價值 442,000 美元，此前在上個季度又購買了 471 股。Turtle Creek Wealth Advisors LLC 在第二季度獲得了強生的新持倉，價值約為 1,224,000 美元。最後，WealthPlan Investment Management LLC 在第二季度將其在強生的持倉增加了 20.2%。WealthPlan Investment Management LLC 目前持有 70,070 股該公司的股票，價值 10,703,000 美元，此前在上個季度又購買了 11,759 股。目前 69.55% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師升級和降級</h2>
</div><p>JNJ has been the subject of a number of research analyst reports. Cowen reaffirmed a &#34;buy&#34; rating on shares of Johnson &amp; Johnson in a research note on Tuesday. Wells Fargo &amp; Company set a $212.00 target price on shares of Johnson &amp; Johnson and gave the stock an &#34;overweight&#34; rating in a research note on Friday, October 3rd. Morgan Stanley set a $190.00 target price on shares of Johnson &amp; Johnson in a research note on Wednesday. Barclays boosted their target price on shares of Johnson &amp; Johnson from $165.00 to $176.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Thursday, July 17th. Finally, Stifel Nicolaus boosted their target price on shares of Johnson &amp; Johnson from $165.00 to $190.00 and gave the stock a &#34;hold&#34; rating in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $199.59.</p>
<div class="lb-trans"><p>強生的股票曾多次成為研究分析師報告的主題。Cowen 在週二的研究報告中重申了對強生股票的 “買入” 評級。富國銀行在 10 月 3 日的研究報告中對強生股票設定了 212.00 美元的目標價，並給予該股票 “超配” 評級。摩根士丹利在週三的研究報告中對強生股票設定了 190.00 美元的目標價。巴克萊在 7 月 17 日的研究報告中將強生股票的目標價從 165.00 美元提高至 176.00 美元，並給予該股票 “持平” 評級。最後，Stifel Nicolaus 在週三的研究報告中將強生股票的目標價從 165.00 美元提高至 190.00 美元，並給予該股票 “持有” 評級。兩位股票研究分析師對該股票給予了強烈買入評級，十二位給予了買入評級，八位給予了持有評級。根據 MarketBeat.com 的數據，該股票的平均評級為 “適度買入”，共識目標價為 199.59 美元。</p>
</div><ul>
<li>Johnson &amp; Johnson Stock Can Keep Rising as Strategy Pays Off</li>
</ul>
<div class="lb-trans"><ul>
<li>強生股票可以繼續上漲，因為戰略奏效</li>
</ul>
</div><p><strong>View Our Latest Report on JNJ</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 JNJ 的最新報告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買賣</h2>
</div><p>In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Insiders own 0.16% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，執行副總裁 Jennifer L. Taubert 在 9 月 4 日（星期四）出售了 56,471 股該公司的股票。股票以 177.81 美元的平均價格出售，總價值為 10,041,108.51 美元。交易完成後，該執行副總裁持有 178,013 股公司股票，價值 31,652,491.53 美元。這代表其持股減少了 24.08%。該交易已在向證券交易委員會的備案中披露，相關信息可通過 SEC 網站獲取。內部人士持有該公司 0.16% 的股票。</p>
</div><h2>Johnson &amp; Johnson Trading Up 0.6%</h2>
<div class="lb-trans"><h2>強生股票上漲 0.6%</h2>
</div><ul>
<li>Why AbbVie and Johnson &amp; Johnson Could Outperform Pfizer</li>
</ul>
<div class="lb-trans"><ul>
<li>為什麼 AbbVie 和強生可能會超越輝瑞</li>
</ul>
</div><p>JNJ opened at $193.27 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a market cap of $465.45 billion, a price-to-earnings ratio of 18.65, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The firm has a 50 day simple moving average of $180.49 and a 200 day simple moving average of $164.86. Johnson &amp; Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.40.</p>
<div class="lb-trans"><p>強生在週五的開盤價為 193.27 美元。該公司的債務與股本比率為 0.50，流動比率為 1.01，速動比率為 0.76。該公司的市值為 4654.5 億美元，市盈率為 18.65，市盈增長比率為 2.27，貝塔係數為 0.40。該公司有 50 日簡單移動平均線為 180.49 美元，200 日簡單移動平均線為 164.86 美元。強生的 52 周低點為 140.68 美元，52 周高點為 194.40 美元。</p>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson &amp; Johnson had a net margin of 27.26% and a return on equity of 33.08%. On average, sell-side analysts anticipate that Johnson &amp; Johnson will post 10.58 earnings per share for the current year.</p>
<div class="lb-trans"><p>強生（NYSE:JNJ - 獲取免費報告）最近在 8 月 30 日（星期三）發佈了季度財報。該公司報告本季度每股收益為 2.26 美元。該業務在本季度的收入為 240.2 億美元。強生的淨利潤率為 27.26%，股本回報率為 33.08%。平均而言，賣方分析師預計強生在當前年度的每股收益為 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Announces Dividend</h2>
<div class="lb-trans"><h2>強生宣佈分紅</h2>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson &amp; Johnson's dividend payout ratio is presently 50.19%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了季度分紅，將於 12 月 9 日（星期二）支付。11 月 25 日（星期二）的股東將獲得 1.30 美元的分紅。這代表每年 5.20 美元的分紅和 2.7% 的收益率。該分紅的除息日為 11 月 25 日（星期二）。強生的分紅支付比率目前為 50.19%。</p>
</div><h2>Johnson &amp; Johnson Company Profile</h2>
<div class="lb-trans"><h2>強生公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>強生是一家控股公司，專注於醫療保健領域的產品研究、開發、生產和銷售。它通過創新藥物和醫療技術兩個部門運營。創新藥物部門專注於免疫學、傳染病、神經科學、腫瘤學、心血管和代謝以及肺動脈高壓。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>What Are Some of the Best Large-Cap Stocks to Buy?</li>
<li>Johnson &amp; Johnson's M&amp;A Strategy Is the Real Story for Investors</li>
<li>How to start investing in penny stocks</li>
<li>Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?</li>
<li>Technology Stocks Explained: Here's What to Know About Tech</li>
<li>Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過強生</li>
<li>目前有哪些值得購買的大盤股？</li>
<li>強生的併購策略才是投資者真正需要關注的故事</li>
<li>如何開始投資於便士股票</li>
<li>特斯拉：一些分析師預測將下跌 30%——該恐慌了嗎？</li>
<li>科技股解析：你需要了解的科技知識</li>
<li>對美元的對沖基金態度轉變——這三隻股票的買入信號？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對強生持有股份的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取強生（NYSE:JNJ - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元於強生嗎？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮強生之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而強生並不在名單上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然強生目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Praxis Investment Management Inc. 在強生公司 $JNJ 中持有 759 萬美元的股份